#### Check for updates

#### **OPEN ACCESS**

EDITED BY Mario F. Juruena, King's College London, United Kingdom

REVIEWED BY Francesco Monaco, Azienda Sanitaria Locale Salerno, Italy Abdul-Rahman Hudaib, AIZH Statistics, Melbourne, Australia

\*CORRESPONDENCE Yan Chen 2524258456@qq.com Jiaqi Song Songjiaqi@pku.edu.cn

<sup>†</sup>These authors have contributed equally to this work

RECEIVED 08 October 2024 ACCEPTED 01 May 2025 PUBLISHED 03 June 2025

#### CITATION

Li W, Hu N, Gao X, Song Y, Zhang R, Sun S, Tong J, Shen Y, Yu Y, Yang K, Chen Y and Song J (2025) Trend of electroconvulsive therapy use and its relationships with clinical characteristics from a large psychiatric center in China. *Front. Psychiatry* 16:1508044. doi: 10.3389/fpsyt.2025.1508044

#### COPYRIGHT

© 2025 Li, Hu, Gao, Song, Zhang, Sun, Tong, Shen, Yu, Yang, Chen and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Trend of electroconvulsive therapy use and its relationships with clinical characteristics from a large psychiatric center in China

Wei Li<sup>1</sup>, Na Hu<sup>1</sup>, Xiaoxiao Gao<sup>1</sup>, Yanying Song<sup>1</sup>, Rongzhen Zhang<sup>1</sup>, Shiyou Sun<sup>1</sup>, Jinghui Tong<sup>1</sup>, Yang Shen<sup>1</sup>, Yongjun Yu<sup>1</sup>, Kebing Yang<sup>1</sup>, Yan Chen<sup>2\*†</sup> and Jiaqi Song<sup>1\*†</sup>

<sup>1</sup>Beijing Huilongguan Hospital, Beijing, China, <sup>2</sup>Huilongguan Clinical Medical School, Peking University, Beijing Huilongguan Hospital, Beijing, China

**Background:** Recent studies on electroconvulsive therapy (ECT) have reported inconsistent frequencies of ECT use in various countries. Therefore, this study aimed to investigate the trends of ECT use in a large psychiatric center in China over 6 consecutive years.

**Methods:** A total of 22,120 inpatients, aged 18–59 years, admitted during the period 2015–2020 to a large grade-A tertiary psychiatric center in Beijing were enrolled in this retrospective study. Demographic and clinical data including vital signs; daily living abilities(ADL); emergency referrals; psychiatric and physical prescriptions were collected from an electronic medical records system.

**Results:** In all, 2,213 (10.0%) inpatients received ECT, with an average number of sessions of  $10.3 \pm 6.6$ . There were no significant differences between the ECT and non-ECT groups in terms of educational level, marital status, length of hospital stay, and blood pressure. After using the propensity score matching (PSM) method, Multiple logistic regression analysis revealed that ECT use was independently associated with married/cohabitating (OR = 1.21, 95% CI: 1.03-1.43); few hospitalizations (OR = 0.96, 95% CI: 0.93-0.99); unemployed (OR = 1.43, 95% CI: 1.16-1.76); emergency referral (OR = 1.62, 95% CI: 1.36-1.93); increased use of antipsychotics (OR = 2.63, 95% CI: 1.88-3.68), mood stabilizers (OR = 1.30, 95% CI: 1.01-1.67), antidepressants (OR = 1.40, 95% CI: 1.13-1.73), and trihexyphenidyl (OR = 1.30, 95% CI: 1.05-1.50); reduced use of hypoglycemic drugs (OR = 0.64, 95% CI: 0.45-0.83); fast heart rate (OR = 1.01, 95% CI: 1.01-1.02); and severe impairments in ADL. Compared with that in 2015 (13.2%), ECT use decreased annually from 2016 (12.4%) to 2019 (9.6%), especially in 2020 (5.7%), given the impact of the COVID-19 pandemic in China.

**Conclusions:** The ECT usage and year-by-year decrease in ECT use in this study were consistent with the recent trends in other regions. Patients with the married/cohabitating, unemployed, and emergency-referral, unstable vital signs, more severe disability received ECT for quick alleviation of their conditions.

KEYWORDS

electroconvulsive therapy, inpatients, China, daily living abilities, clinical characteristic

### Introduction

Electroconvulsive therapy (ECT) is considered a highly effective nonpharmacological intervention for patients with severe psychiatric disorders (1). With the rapid development of psychiatry, there is a growing body of evidence indicating that comprehensive treatment patterns, including medication, psychotherapy, physical therapy, and social rehabilitation therapy, are currently the main clinical strategies. ECT plays a crucial role in the acute phase of several serious mental illnesses (2), and its role is incomparable to the roles of medication and psychological therapy (3).

ECT has been used clinically for nearly 90 years since it was first demonstrated in Rome in 1938. The basic mechanism of ECT is the application of a brief electric current to the patient's scalp to induce a generalized seizure that, in turn, alleviates severe psychiatric symptoms (4). As the findings of Leiknes and colleagues' 2012 review (5), Regenold and colleagues' 2022 survey (6), the ECT performed today has remained roughly the same as that in the past decade since the early 20th century. ECT is considered a strict therapeutic strategy for patients with a high risk of suicide, impulsiveness, aggressive tendencies, and resistance to pharmacotherapy (7, 8).

Information on the patterns of ECT use across countries has been inconsistent (5, 9). There had been sustained declining use of ECT in the United States from 1993 to 2009 (10). In contrast, a large survey found that 30% of the patients with mood disorders in southern China received ECT – while the rate is lower than that reported in Beijing (33.6% in 2007 and 61.8% in 2013), it is far higher than the rates reported in European countries and the United States (11, 12). However, with the popularization of ECT usage in mental disease and stigmatization of ECT, it is necessary to update the information on the use of ECT in China in the recent 5 years or even longer (5).

This study retrospectively investigated the ECT use and the correlated demographic and clinical factors by examining data from a large psychiatric hospital in China for a period of 1 January 2015 to 31 December 2020.

## Methods

#### Subjects and ECT setting

The study was conducted at Beijing Huilongguan Hospital, Huilongguan Clinical Medical School, Peking University, China. This center has 1369 beds and is one of the largest grade-A tertiary psychiatric hospitals in Beijing and even in China. In this hospital, ECT is primarily administered to inpatients. For adult patients, the ECT course usually comprises 6-12 sessions under general anesthesia, over 2-3 weeks (13). The anesthesia and muscle relaxation is induced with propofol (1–1.5 mg/kg) accompanied by succinylcholine (0.3–0.7 mg/kg) and oxygenation. The intensity of ECT is based on two-thirds of the patient's age (14).

ECT is delivered via the electrodes of a MECTA spectrum M5000Q stimulator (MECTA Corp, Tualatin, Oregon, USA) that are placed on the bilateral temporal lobes. The following ECT parameters are used: maximum charge delivered, 504 mC; output current, 0.9 A; frequency, 10 to 70 Hz; pulse width, 1.0 ms; maximum stimulus duration, 8 s (15). After each ECT session, the patient is transferred to the recovery room for close monitoring.

# Collection of demographic and clinical characteristics

The information of all patients aged 18–59 years who were receiving adult psychiatric services was retrieved from the electronic medical record system (EMRS). The following inpatient data were collected: basic demographic and clinical characteristics including the diagnoses, psychiatric and physical (non-psychiatric) prescriptions, emergency referrals, vital signs, and ADL performance.

Psychiatric diagnoses were divided into four categories: schizophrenia or other psychotic disorders (SZ), bipolar disorders (BD), major depressive disorders (MDD), and others. The diagnosis was confirmed by two experienced psychiatrists according to the diagnostic criteria of the International Statistical Classification of Diseases and Related Health Problems (ICD-10). If a patient had more than one diagnosis, only the primary diagnosis was used.

Vital signs, including systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate, was considered one of the crucial indicators for indirectly assessing the stability of physical conditions. Unstable physical conditions can also have an negative impact on mental illnesses, such as the blood pressure variability increasing the risk of anxiety (16). These indicators were recorded and calculated as the average of measurements before each ECT using a unified electronic sphygmomanometer. The accuracy of an electronic sphygmomanometer is usually verified every 6 months.

Generally, the blood pressure and heart rate in the right upper limb is measured while the patient is seated.

ADL performance, an important outcome evaluated in this study, was assessed using the Barthel ADL Index at admission and discharge (17). The ADL index includes 10 items (feeding, transfer, personal hygiene, toilet use, bathing, walking, going up and down stairs, dressing, stool, and urination). ADL ability was classified as follows according to the ADL score (range: 0–100): ADL self-care (100), mild ADL disability (65–95), moderate ADL disability (45–60) and severe ADL disability (0–40). Low scores indicate impairments in ADL (18). Cronbach's alpha for ADL was 0.94 (19).

The authors (X.X.G and J.H.T.) and a technician responsible for EMRS collected the data and established the study database. The study design was approved by the Ethics Committee of Beijing Huilongguan Hospital.

#### Statistical analysis

All data were analyzed using SPSS software (version 22.0; SPSS Inc., Chicago, IL, USA). Basic demographic and clinical characteristics between the ECT and non-ECT groups were compared using the chi-square test for categorical variables and the Mann–Whitney U test for continuous non-normally distributed variables, as appropriate. To reduce bias and confounding variables, propensity score matching (PSM) analysis was conducted on participants based on gender and age, with matching pairs on 1:1. SPSS software was used to calculate conditional logistic regression between the paired data. The odds ratio (OR) and 95% confidence interval (CI) for each variable were calculated. Finally, the trends and use rate in ECT among the four disease types from 2015 to 2020 were analyzed separately. The level of significance was set at 0.05 (two-tailed).

## Results

The data of 22,120 patients who were hospitalized during the study period and met the study criteria were analyzed. The mean age was  $41.8 \pm 12.7$  years, the length of current hospital stay was  $71.8 \pm 68.2$  days, and the number of hospitalizations was  $7.4 \pm 7.9$ ; 57.1% of the sample consisted of men; 59.5%, 14.7%, 12.6%, and 13.2% had a primary diagnosis of SZ, BD, MDD, and other, respectively. The most frequently prescribed medication class was antipsychotics (89.6%), followed by trihexyphenidyl (30.7%), antidepressants (25.8%), mood stabilizers (21.9%), and cognitive-enhancing drug (0.4%). Commonly prescribed drugs for physical diseases included lipid-lowering drugs (24.0%), hypoglycemic drugs (11.6%), and anti-hypertensive drugs (11.1%).

Table 1 outlines the demographic and clinical characteristics of the study sample and the results of the comparative analyses between the ECT and non-ECT groups. Of these, 2213 individuals (10.0%) underwent ECT. The corresponding proportions were 17.8% for BD, 17.8% for MDD, 8.2% for SZ, and 2.1% for other diagnoses (P<0.001). There were significant differences in all demographic and clinical characteristics, except education, marital status, nationality, religion, current hospital stay, and DBP and SBP before ECT between the two groups (Table 1).

After the PSM based on gender and age and matching pairs on 1:1, Supplementary Table 1 outlines the demographic and clinical characteristics of the paired sample (2213 patients in each group). Compared with the comparison results of the previously unmatched group, there were differences in gender, age, marital status, use of antihypertensive drugs, use of lipid-lowering drugs, and ADL total at discharge among the paired samples, while other results were generally consistent.

Conditional logistic regression analysis showed that married/ cohabitating, unemployed, emergency admissions were significantly associated with the use of ECT ( $OR_1 = 1.21, 95\% CI_1: 1.03-1.43$ )  $(OR_2 = 1.43, 95\% CI_2: 1.16-1.76)$   $(OR_3 = 1.62, 95\% CI_3: 1.36-1.93)$ . The use of antipsychotics, mood stablilizers, antidepressants and trihexyphenidyl were also significantly associated with the use of ECT (OR<sub>1</sub> = 2.63, 95% CI<sub>1</sub>: 1.88-3.68) (OR<sub>2</sub> = 1.30, 95% CI<sub>2</sub>: 1.01-1.67) (OR<sub>3</sub> = 1.40, 95% CI<sub>3</sub>: 1.13-1.73) (OR<sub>4</sub> = 1.30, 95% CI<sub>4</sub>: 1.05-1.50). Patients with mild, moderate and severe ADL disability had 1.56 times (95% CI: 1.36-1.79), 5.95 times (95% CI: 4.51-7.85), 10.14 times (95% CI: 4.15-24.80) higher risk of using ECT compared to the ADL self-living individuals. Patients with diagnosing schizophrenia, bipolar disorder and major depression had 5.62 times (95% CI: 3.97-7.94), 7.55 times (95% CI: 4.86-11.73), 8.99 times (95% CI: 14.00-21.84) higher risk of using ECT compared to the individuals with other diagnosis. The use of hypoglycemic drugs (OR = 0.64, 95% CI: 0.45-0.83), hospitalizations (OR = 0.96, 95% CI: 0.93-0.99) were negatively associated with the use of ECT. The effect of heart rate was relatively small but still statistically significant (OR = 1.01, 95% CI: 1.01-1.02) (Figure 1).

In addition, compared to ECT use on 2015, ECT use decreased significantly from 2016 to 2020. In 2020, when all aspects of life were negatively affected by the COVID-19 pandemic in China, the number of patients receiving ECT treatment was the lowest (Figure 2).

## Discussion

This observational study found that 10.0% of 22,120 inpatients in Beijing's largest Grade A tertiary psychiatric hospital between 2016 and 2020 received ECT. We analyzed the largest single center ECT data in China in the past eight years. In contrast to previous studies, our research included detailed basic demographic and clinical characteristics as well as analyzed the vital signs and ADL ability of inpatients. Finally, we found that the receipt of ECT was independently associated with Married/cohabitating; few hospitalizations; unemployed; emergency referral; reduced use of hypoglycemic drugs; fast heart rate; severe ADL disability; and primary diagnoses of BD, MDD, and SCH.

We found that 10% of the inpatients received ECT, and this rate is slightly lower than that reported at a Chinese psychiatric hospital outside the Beijing area (17.8%) (12). Moreover, another study conducted in the Beijing area reported an ECT rate of 57.7% (11),

#### TABLE 1 Demographic and characteristics of the study sample.

Characteristics	The whole sample(n=22120)		Non-ECT group (n=19907)		ECT group (n=2213)		Statistics		
	N	%	N	%	N	%	Х <sup>2</sup>	Df	Р
Male, N(%)	12629	57.1	11818	59.4	811	36.6	419.6	1	< 0.001
Education(Undergraduate)	11510	52.0	10411	52.3	1099	49.7	3.5	1	0.61
Married/cohabitating	11163	50.5	10053	50.5	1110	50.2	0.04	1	0.85
Han nationality	21597	97.6	19432	97.6	2165	97.8	0.4	1	0.52
Religion(No religious belief)	20892	94.4	18812	94.5	2080	94.0	0.5	1	0.45
Local resident	13985	63.2	13039	65.5	946	42.7	443.4	1	< 0.001
Employed	18556	83.9	16791	84.3	1765	79.8	31.1	1	< 0.001
Emergency in hospital	4240	19.2	3438	17.3	802	36.2	462.6	1	< 0.001
Primary psychiatric diagnosis							654.5	3	< 0.001
Schizophrenia-spectrum disorders	13155	59.5	12077	60.7	1078	48.7			
Bipolar disorder	3259	14.7	2680	13.5	579	26.2			
Major depression	2779	12.6	2285	11.5	494	22.3			
Others	2927	13.2	2865	14.4	62	2.8			
Psychiatric drugs									
Use of antipsychotics	19818	89.6	17758	89.2	2060	93.1	32.2	1	< 0.001
Use of mood stabilizers	4844	21.9	4152	20.9	692	31.3	126.3	1	< 0.001
Use of antidepressants	5710	25.8	4850	24.4	860	38.9	218.6	1	< 0.001
Use of cognitive-enhancing drug	88	0.4	86	0.4	2	0.1	5.9	1	0.019
Use of trihexyphenidyl	6796	30.7	5938	29.8	858	38.8	74.8	1	< 0.001
Physical disease drugs									
Use of antihypertensive drugs	2248	11.1	2289	11.5	159	7.2	37.7	1	< 0.001
Use of lipid-lowering drugs	5306	24.0	4881	24.5	425	19.2	30.9	1	< 0.001
Use of hypoglycemic drugs	2576	11.6	2482	12.5	94	4.2	130.8	1	< 0.001
Year							127.8	5	< 0.001
2015	3376	15.3	2931	14.7	445	20.1			
2016	3570	16.1	3128	15.7	442	20.0			
2017	3926	17.7	3537	17.8	389	17.6			
2018	4163	18.8	3788	19.0	375	16.9			
2019	4106	18.6	3713	18.7	393	17.8			
2020	2979	13.5	2810	14.1	169	7.6			
	м	SD	м	SD	м	SD	Ζ		Р
Age	41.8	12.7	42.5	12.6	35.7	12.2	-23.8		< 0.001
Current hospital stay (days)	71.8	68.2	72.4	69.1	66.5	59.7	-0.8		0.45
No. of hospitalizations	7.4	9.7	7.9	9.9	2.6	3.3	-30.3		< 0.001
Heart rate (/min)	81.2	12.4	81.0	12.5	83.0	12.1	-9.5		< 0.001
SBP before ECT course (mmHg)	117.7	12.9	117.8	12.8	117.4	13.9	-0.8		0.41
DBP before ECT course (mmHg)	76.0	8.6	76.0	8.5	76.0	9.4	-0.2		0.89

(Continued)

TABLE 1 Continued	TABLE 1 C	ontinued
-------------------	-----------	----------

Characteristics	The whole sample(n=22120)		Non-ECT group (n=19907)		ECT group (n=2213)		Statistics		
Characteristics	N	%	N	%	N	%	X <sup>2</sup>	Df	Р
	М	SD	м	SD	М	SD	Ζ		Р
ADL total at admission	91.6	10.6	92.2	10.1	87.2	13.1	-20.1		< 0.001
ADL total at discharge	96.1	8.2	96.0	8.2	96.9	7.6	-8.5		< 0.001
Changes in ADL total	4.2	8.4	3.8	7.5	9.7	12.3	-30.4		< 0.001
No. Sessions of ECT					10.3	6.6			
The intensity of ECT (J)					27.7	15.2			
Seizure duration (s)					49.2	23.1			

SBP, systolic blood pressure; DBP, diastolic blood pressure; ADL, daily living abilities.

and the frequency of ECT use in our study was closer to that reported in foreign countries: 1.2-7.4% in the USA, 13.6% in Japan, 13.8% in India, and 6% in Denmark (10, 20-25). This difference in the rates between China and these countries can be attributed to an inconsistent understanding of ECT indications among different hospitals. In addition, our treatment principle of focusing on early prevention of mental illness and reducing the possibility of severe mental diseases requiring ECT may also explain some of these differences. Of note, the annual decline in ECT use in our study was roughly consistent with the global trends (10, 26). In particular, the lowest uptake of ECT was reported in 2020 - when the COVID-19 pandemic impacted ECT services worldwide. During the COVID-19 period, several realistic factors limited the use of ECT, such as: the ECT operation room needing longer time for disinfection (about twice the usual time), patients without the cold symptoms (not considered as a source of viral infection), manpower shortage (many doctors were appointed to service nucleic acid testing), and patients restricted in their own wards (to reduce virus transmission) (27, 28).

ECT is commonly assumed to be a primary (first-line) treatment with strict indications, referring to the clinical guidelines of five authoritative psychiatric associations (American Psychiatric Association, Canadian Network for Mood and Anxiety Treatments, The Royal Australian and New Zealand College of Psychiatrists, The Royal College of Psychiatrists, and World Federation of Societies of Biological Psychiatry) (29–33). In China, patients with high suicide/aggressive behavior risk, food/ fluid refusal, stupor, and extreme lack of cooperation or treatment resistance are given priority for ECT (34). Similar to our findings, ECT is used more frequently for BD or MDD inpatients (35). According to authoritative reviews and international guidelines, ECT can also be used to relieve symptoms of treatment-resistant schizophrenia; however, attention should be paid to its benefits and side effects.

From the initial results, we speculate that younger and female patients were more likely to receive ECT, which is consistent with other results (12), Demographically, there was a predominance of female patients of 53.4% in our results, 51% in Japan (36), 56% in Pakistan (37), 60% in Saudi Arabia (38), 71% in Australia (39),

57.7%-60.1% in Sweden (40, 41), 61.0% in Poland (42) and 57% in Norway (43). Our analysis of sex distribution in affective disorders showed that there were a higher proportion of female, up to 62%. We realize that the higher proportion of female in ECT is a global trend, especially in Western countries where ECT originated (44). This may be related to factors such as the higher prevalence of mental disorders among women, their susceptibility to hormones and environmental variability (45). On the contrary, in several African regions (29%-46%) (46, 47) and other Asian countries [28% in Katmandu (48); 39% in India (49)], the proportion of women in ECT is relatively low. This the specific reasons maybe need further investigations. However, from another perspective, the above different results are not inconsistent and may be related to bias and confounding factors. Therefore, we further conducted PSM analysis based on gender and age, with matching pairs on 1:1.

After PSM analysis, the figure clearly shows that the use of ECT was independently associated with fewer hospitalizations, confirming earlier results that ECT may reduce readmission rates through satisfactory treatment outcomes (50). Our analysis showed that the status of being married was associated with the use of ECT. One possible explanation is that being married was associated with family members recognizing of faster disease relief through the use of ECT (51). We speculate that unemployment may be an aspect of impaired social functioning in patients with mental illness. This suggested that the disease may be more severe and patients may be more likely to choose ECT to get quickly improvement and restore their health (52).

Notably, this is the first retrospective study to explore the relationship between the use of ECT and severity (including assessment of emergency, vital signs, and physical prescriptions). The results showed that more than one-third of the patients in the ECT group were referred from emergency departments. Emergency hospitalization may provide a fast and effective therapeutic opportunity for patients at risk, including receiving ECT services. In previous studies, the heart rate was associated with disease severity and urgency (53, 54). In addition, the different result of hypoglycemic drugs in Figure 1 maybe need further research to verify the differences (55).

Variables	<u> </u>		Odds Ratio(95%Cl)	<b><i>P</i></b> value
Married/cohabitating	-	-	1.21(1.03–1.43)	0.022
Unemployed	-	<b>-</b>	1.43(1.16–1.76)	0.001
Emergency in hospital		<b>—</b>	1.62(1.36–1.93)	<0.001
Use of antipsychotics		<b>_</b>	2.63(1.88–3.68)	<0.001
Use of mood stabilizers	-	-	1.30(1.01–1.67)	0.045
Use of antidepressants	-	•	1.40(1.13–1.73)	0.002
Use of hypoglycemic drugs			0.64(0.45–0.92)	0.012
Use of trihexyphenidyl	-	<b>-</b>	1.30(1.05–1.50)	0.017
ADL self-living	•		1	
Mild ADL disability		- <b>-</b> -	1.56(1.36–1.79)	<0.001
Moderate ADL disability			5.95(4.51–7.85)	<0.001
Severe ADL disability			10.14(4.15–24.80)	0.006
Other diagnosis	•		1	
Schizophrenia		<b></b>	5.62(3.97–7.94)	<0.001
Bipolar disorder		<b></b>	7.55(4.86–11.73)	<0.001
Major depression			8.99(14.00–21.84)	<0.001
No. hospitalizations	•		0.96(0.93–0.99)	0.007
Heart rate(/min)	•		1.01(1.00–1.02)	0.002
		2 3 3 7 11 15	5 19 23 27	

FIGURE 1

Independent contributors to ECT (multiple logistic regression analysis).



Diminished ADL is often regarded as a characteristic feature of severe mental disorders (56), such as the incapacity of individuals with profound depression or impulsivity to effectively accomplish certain activities in their daily lives (57). Consistent with our viewpoint, another study found the patients with ECT had worse ADL score compared to those without ECT. As shown in our results, the degree of ADL disability at admission is a positive factor for predicting acceptance of ECT treatment (58). Previous studies have shown that psychiatric patients in the acute phase have varying degrees of impairment in the self-care and daily life (59). During the rehabilitation period, except for severe organic psychiatric disorders, the impaired daily living abilities will get recovery for most patients (60). This is as observed in Table 1 of this article.

#### Limitations

This study had several limitations. First, the results of this retrospective study should be considered with caution owing to methodological limitations. Second, the data were collected from a single center, and the findings are not entirely applicable to other regions of China. Third, although our study included relevant variables such as non-psychiatric prescriptions and vital signs, evaluation data on the severity of psychiatric symptoms were still lacking. Finally, some specific indications like catatonia were not been extracted, and might be classified as special symptoms of a disease, not been independently diagnosed. Nevertheless, we analyzed a large dataset covering 6 consecutive years to determine the pattern of ECT use and the factors correlated with ECT usage from a large psychiatric center in China over the last years.

# Conclusion

In conclusion, this study found that the usage rate and yearly decreasing trend in ECT use in the largest tertiary psychiatric center in Beijing were roughly consistent with the recent trends in other regions. ECT use was associated with married/cohabitating; unemployed; few hospitalizations; emergency referral; increased use of antipsychotics, mood stabilizers, antidepressants; reduced use of hypoglycemic drugs; fast heart rate; and severe ADL disability. Given the variations in previous research findings, it is crucial for clinical psychiatrists to adopt a scientific approach and the evidence based practice when establishing ECT protocols that adhere to the ECT utilization standards.

# Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

## **Ethics statement**

The studies involving humans were approved by The Ethics Committee of Beijing Huilongguan Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

# Author contributions

WL: Data curation, Funding acquisition, Writing – original draft. NH: Data curation, Funding acquisition, Investigation, Writing – review & editing. XG: Data curation, Funding acquisition, Investigation, Writing – review & editing. YSo: Data curation, Formal Analysis, Methodology, Writing – review & editing. RZ: Investigation, Validation, Writing – review & editing. SS:. JS(first author): Data curation, Investigation, Writing – review & editing. JT: Data curation, Formal Analysis, Writing – review & editing. YSh: Data curation, Formal Analysis, Writing – review & editing. YY: Data curation, Investigation, Supervision, Writing – review & editing. KY: Data curation, Validation, Writing – review & editing, Methodology. YC: Data curation, Formal Analysis, Investigation, Writing – review & editing. JS(second author): Data curation, Funding acquisition, Investigation, Writing – review & editing.

# Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the research fund of Capital's Funds for Health Improvement and Research (Initial project2020-2-2134, 2024-4-2134) and Beijing Hospitals Authority Youth Programme under Grant No. QML20232006 and QML20232003, and the LongYue Program of Beijing Huilongguan Hospital under Grant Nos. LY202302.

## Acknowledgments

We would like to acknowledge all participants involved in this study.

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# **Generative AI statement**

The author(s) declare that no Generative AI was used in the creation of this manuscript.

### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2025. 1508044/full#supplementary-material

#### SUPPLEMENTARY TABLE 1

Demographic and characteristics of the two groups by propensity score matching (PSM).

## References

1. Benson NM, Seiner SJ. Electroconvulsive therapy in children and adolescents: clinical indications and special considerations. *Harv Rev Psychiatry*. (2019) 27:354–8. doi: 10.1097/HRP.00000000000236

2. Fink M. What was learned: studies by the consortium for research in ECT (CORE) 1997-2011. Acta Psychiatr Scand. (2014) 129:417-26. doi: 10.1111/acps.2014.129.issue-6

3. Kellner CH, Obbels J, Sienaert P. When to consider electroconvulsive therapy (ECT). Acta Psychiatr Scand. (2020) 141:304–15. doi: 10.1111/acps.v141.4

4. Sumia P, Seppälä N, Ritschkoff J, Tammentie-Sarèn T, Leinonen E, Järventausta K. A survey of electroconvulsive therapy in Finland. *J ECT*. (2021) 37:36–9. doi: 10.1097/YCT.000000000000709

5. Leiknes KA, Jarosh-von Schweder L, Høie B. Contemporary use and practice of electroconvulsive therapy worldwide. *Brain Behav.* (2012) 2:283–344. doi: 10.1002/brb3.37

6. Rohde P, Noorani R, Feuer E, Lisanby SH, Regenold WT. Electroconvulsive therapy across nations: A 2022 survey of practice. J ECT. (2024) 40:96-104. doi: 10.1097/YCT.00000000000980

7. Dierckx B, Heijnen WT, van den Broek WW, Birkenhäger TK. Efficacy of electroconvulsive therapy in bipolar versus unipolar major depression: a metaanalysis. *Bipolar Disord*. (2012) 14:146–50. doi: 10.1111/j.1399-5618.2012.00997.x

8. Tor PC, Tan XW, Martin D, Loo C. Comparative outcomes in electroconvulsive therapy (ECT): A naturalistic comparison between outcomes in psychosis, mania, depression, psychotic depression and catatonia. *Eur Neuropsychopharmacol.* (2021) 51:43–54. doi: 10.1016/j.euroneuro.2021.04.023

9. Sackeim HA. Modern electroconvulsive therapy: vastly improved yet greatly underused. JAMA Psychiatry. (2017) 74:779–80. doi: 10.1001/jamapsychiatry.2017.1670

 Case BG, Bertollo DN, Laska EM, Price LH, Siegel CE, Olfson M, et al. Declining use of electroconvulsive therapy in United States general hospitals. *Biol Psychiatry*. (2013) 73:119–26. doi: 10.1016/j.biopsych.2012.09.005

11. Wang ZM, Zhu H, Pan YL, Chiu HF, Correll CU, Ungvari GS, et al. Electroconvulsive therapy and its association with demographic and clinical characteristics in Chinese psychiatric patients. *J ECT*. (2015) 31:114–8. doi: 10.1097/ YCT.000000000000181

12. Ma Y, Rosenheck R, Fan N, He H. Rates and patient characteristics of electroconvulsive therapy in China and comparisons with the United States. *J ECT*. (2019) 35:251–7. doi: 10.1097/YCT.00000000000589

13. Hirano J, Takamiya A, Yamagata B, Hotta S, Miyasaka Y, Pu S, et al. Frontal and temporal cortical functional recovery after electroconvulsive therapy for depression: A longitudinal functional near-infrared spectroscopy study. *J Psychiatr Res.* (2017) 91:26–35. doi: 10.1016/j.jpsychires.2017.02.018

14. Hossain A, Sullivan P. The effects of age and sex on electroconvulsive therapy using remifentanil as the sole anesthetic agent. *J ECT*. (2008) 24:232–5. doi: 10.1097/ YCT.0b013e3181617260

15. Wang J, Jiang Y, Tang Y, Xia M, Curtin A, Li J, et al. Altered functional connectivity of the thalamus induced by modified electroconvulsive therapy for schizophrenia. *Schizophr Res.* (2020) 218:209–18. doi: 10.1016/j.schres.2019.12.044

16. Lim LF, Solmi M, Cortese S. Association between anxiety and hypertension in adults: A systematic review and meta-analysis. *Neurosci Biobehav Rev.* (2021) 131:96–119. doi: 10.1016/j.neubiorev.2021.08.031

17. Yi Y, Ding L, Wen H, Wu J, Makimoto K, Liao X. Is barthel index suitable for assessing activities of daily living in patients with dementia. *Front Psychiatry.* (2020) 11:282. doi: 10.3389/fpsyt.2020.00282

18. Karlsson Å, Lindelöf N, Olofsson B, Berggren M, Gustafson Y, Nordström P, et al. Effects of geriatric interdisciplinary home rehabilitation on independence in activities of daily living in older people with hip fracture: A randomized controlled trial. *Arch Phys Med Rehabil.* (2020) 101:571–8. doi: 10.1016/j.apmr.2019.12.007

19. Zhang X, Lin L, Sun X, Lei X, Liu GG, Raat H, et al. Development and validation of the disability index among older adults. *J Gerontol A Biol Sci Med Sci.* (2023) 78:111–9. doi: 10.1093/gerona/glac059

20. Andrade C, Gangadhar BN. ECT devices in India. J ECT. (2005) 21:253–4. doi: 10.1097/01.yct.0000183897.09302.54

21. Chanpattana W. One hundred twenty years of mental health care in Thailand and the development of electroconvulsive therapy. *J ECT*. (2010) 26:11–3. doi: 10.1097/ YCT.0b013e3181c185f9

22. Gazdag G, Dragasek J, Takács R, Lõokene M, Sobow T, Olekseev A, et al. Use of electroconvulsive therapy in Central-Eastern European countries: an overview. *Psychiatr Danub.* (2017) 25:366–70. doi: 10.24869/psyd.2017.136

23. Yamazaki R, Ohbe H, Matsuda Y, Kito S, Morita K, Matsui H, et al. Early electroconvulsive therapy in patients with major depressive disorder: A propensity score-matched analysis using a nationwide inpatient database in Japan. *J ECT*. (2021) 37:176–81. doi: 10.1097/YCT.00000000000763

24. Luccarelli J, Henry ME, Smith F, Beach SR, McCoy TH Jr. Changes in inpatient electroconvulsive therapy utilization between 2019 and 2020: A national inpatient sample analysis. *J ECT*. (2023) 39:173–8. doi: 10.1097/YCT.00000000000917

25. Pedersen MI, Salagre E, Kellner CH, Rohde C, Østergaard SD. The use of electroconvulsive therapy (ECT) en bloc in Denmark: a nationwide register-based study. *Nord J Psychiatry.* (2023) 77:440–6. doi: 10.1080/08039488.2022.2142279

26. Buley N, Copland E, Hodge S, Chaplin R. A further decrease in the rates of administration of electroconvulsive therapy in england. *J ECT*. (2017) 33:198–202. doi: 10.1097/YCT.00000000000374

27. Surve RM, Sinha P, Baliga SP, M R, Karan N, Jl A, et al. Electroconvulsive therapy services during COVID-19 pandemic. *Asian J Psychiatr.* (2021) 59:102653. doi: 10.1016/j.ajp.2021.102653

28. Karl S, Schönfeldt-Lecuona C, Sartorius A, Grözinger M. Provision of electroconvulsive therapy during the COVID-19 pandemic: A survey among clinics in Germany, Austria, and Switzerland. *J ECT*. (2022) 38:205–10. doi: 10.1097/YCT.00000000000846

29. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. *World J Biol Psychiatry*. (2013) 14:334-85. doi: 10.3109/15622975.2013.804195

30. Nielsen RM, Olsen KS, Lauritsen AO, Boesen HC. Electroconvulsive therapy as a treatment for protracted refractory delirium in the intensive care unit–five cases and a review. *J Crit Care*. (2014) 29:881.e1–6. doi: 10.1016/j.jcrc.2014.05.012

31. Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. *Aust N Z J Psychiatry.* (2015) 49:1087–206. doi: 10.1177/0004867415617657

32. Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. *Can J Psychiatry*. (2016) 61:540–60. doi: 10.1177/0706743716659417

33. Coshal S, Jones K, Coverdale J, Livingston R. An overview of reviews on the safety of electroconvulsive therapy administered during pregnancy. *J Psychiatr Pract.* (2019) 25:2–6. doi: 10.1097/PRA.00000000000359

34. Tang YL, Jiang W, Ren YP, Ma X, Cotes RO, McDonald WM. Electroconvulsive therapy in China: clinical practice and research on efficacy. *J ECT*. (2012) 28:206–12. doi: 10.1097/YCT.0b013e31825957b1

35. Li Q, Su YA, Xiang YT, Shu L, Yu X, Ungvari GS, et al. Electroconvulsive therapy in schizophrenia in China: A national survey. *J ECT*. (2017) 33:138–42. doi: 10.1097/ YCT.000000000000361

36. Chanpattana W, Kojima K, Kramer BA, Intakorn A, Sasaki S, Kitphati R. ECT practice in Japan. J ECT. (2005) 21:139–44. doi: 10.1097/01.yct.0000169503.80981.c9

37. Naqvi H, Khan MM. Use of electroconvulsive therapy at a university hospital in Karachi, Pakistan: a 13-year naturalistic review. *J ECT*. (2005) 21:158–61. doi: 10.1097/01.yct.0000177962.76163.44

38. Alhamad AM, al-Haidar F. A retrospective audit of electroconvulsive therapy at King Khalid University Hospital, Saudi Arabia. *East Mediterr Health J.* (1999) 5:255–61. doi: 10.26719/1999.5.2.255

39. Lamont S, Brunero S, Barclay C, Wijeratne C. Evaluation of an electroconvulsive therapy service in a general hospital. *Int J Ment Health Nurs*. (2011) 20:223–9. doi: 10.1111/j.1447-0349.2010.00725.x

40. Popiolek K, Arnison T, Bejerot S, Fall K, Landén M, Nordenskjöld A. Association between electroconvulsive therapy and time to readmission after a manic episode. *Acta Psychiatr Scand.* (2024) 150:22–34. doi: 10.1111/acps.v150.1

41. Rönnqvist I, Nilsson FK, Nordenskjöld A. Electroconvulsive therapy and the risk of suicide in hospitalized patients with major depressive disorder. *JAMA Netw Open*. (2021) 4:e2116589. doi: 10.1001/jamanetworkopen.2021.16589

42. Antosik-Wójcińska AZ, Dominiak M, Mierzejewski P, Jażdżyk P, Gazdag G, Takacs R, et al. Changes in the practice of electroconvulsive therapy in Poland: A nationwide survey comparing data between 2005 and 2020. *Neuropsychiatr Dis Treat.* (2021) 17:605–12. doi: 10.2147/NDT.S296210

43. Schweder LJ, Lydersen S, Wahlund B, Bergsholm P, Linaker OM. Electroconvulsive therapy in Norway: rates of use, clinical characteristics, diagnoses, and attitude. *J ECT*. (2011) 27:292–5. doi: 10.1097/YCT.0b013e318208e24b

44. Wilhelmy S, Brühl AB, Himmighoffen H, Conca A, Grözinger M. Electroconvulsive therapy in Switzerland: A survey on contemporary practice in remembrance of a historical meeting. *J ECT*. (2023) 39:197–201. doi: 10.1097/YCT.00000000000010

45. Lu J, Xu X, Huang Y, Li T, Ma C, Xu G, et al. Prevalence of depressive disorders and treatment in China: a cross-sectional epidemiological study. *Lancet Psychiatry*. (2021) 8:981–90. doi: 10.1016/S2215-0366(21)00251-0

46. Benson-Martin JJ, Milligan PD. A Survey of the Practice of Electroconvulsive Therapy in South Africa. J ECT. (2015) 31:253–7. doi: 10.1097/YCT.00000000000239

47. Subedi S, Aich TK, Sharma N. Use of ECT in Nepal: A One Year Study From the Country's Largest Psychiatric Facility. *J Clin Diagn Res.* (2016) 10:VC01-01VC04. doi: 10.7860/JCDR/2016/14660.7269

48. Subedi S, Aick TK, Sharma N. Use of ECT in Nepal: A One Year Study From the Country's Largest Psychiatric Facility. *J Clin Diagn Res.* (2016) 10:VC01-01VC04. doi: 10.7860/JCDR/2016/14660.7269

49. Chanpattana W, Kunigiri G, Kramer BA, Gangadhar BN. Survey of the practice of electroconvulsive therapy in teaching hospitals in India. *J ECT*. (2005) 21:100–4. doi: 10.1097/01.yct.0000166634.73555.e6

50. Choi KM, Choi SH, Hong JK, Lee MH, Jung JH, Oh SH, et al. The Effects of Continuation-Maintenance Electroconvulsive Therapy on Reducing Hospital Re-Admissions in Patients with Treatment-Resistant Schizophrenia. *Clin Psychopharmacol Neurosci.* (2018) 16:339–42. doi: 10.9758/cpn.2018.16.3.339

51. Ying YB, Jia LN, Wang ZY, Jiang W, Zhang J, Wang H, et al. Electroconvulsive therapy is associated with lower readmission rates in patients with schizophrenia. *Brain Stimul.* (2021) 14:913–21. doi: 10.1016/j.brs.2021.05.010

52. Takamiya A, Kishimoto T, Hirano J, Nishikata S, Sawada K, Kurokawa S, et al. Neuronal network mechanisms associated with depressive symptom improvement following electroconvulsive therapy. *Psychol Med.* (2021) 51:2856-63. doi: 10.1017/S0033291720001518

53. Inoue A, Hifumi T, Kuroda Y, Nishimoto N, Kawakita K, Yamashita S, et al. Mild decrease in heart rate during early phase of targeted temperature management following tachycardia on admission is associated with unfavorable neurological outcomes after severe traumatic brain injury: a *post hoc* analysis of a multicenter randomized controlled trial. *Crit Care.* (2018) 22:352. doi: 10.1186/s13054-018-2276-6

54. Ma X, Wang Z, Wang J, Liu F, Zhang D, Yang L, et al. Admission heart rate is associated with coronary artery disease severity and complexity in patients with acute coronary syndrome. *Angiology*. (2019) 70:774–81. doi: 10.1177/0003319719832376

55. Linnaranta O, Trontti KT, Honkanen J, Hovatta I, Keinänen J, Suvisaari J. Peripheral metabolic state and immune system in first-episode psychosis - A gene expression study with a prospective one-year follow-up. *J Psychiatr Res.* (2021) 137:383–92. doi: 10.1016/j.jpsychires.2021.03.013

56. Kim SJ, Jung DU, Moon JJ, Jeon DW, Seo YS, Jung SS, et al. Effects of an extrinsic motivator on the evaluation of cognitive and daily living functions in patients with schizophrenia. *Schizophr Res.* (2020) 220:172–8. doi: 10.1016/j.schres.2020.03.036

57. He M, Ma J, Ren Z, Zhou G, Gong P, Liu M, et al. Association between activities of daily living disability and depression symptoms of middle-aged and older Chinese adults and their spouses: A community based study. *J Affect Disord*. (2019) 242:135–42. doi: 10.1016/j.jad.2018.08.060

58. An FR, Zhang L, Zhang QE, Ungvari GS, Ng CH, Chiu H, et al. Electroconvulsive therapy and its relationships with clinical characteristics and quality of life in Chinese psychiatric patients. *Psychiatry Res.* (2016) 246:246–9. doi: 10.1016/j.psychres.2016.09.046

59. Wilkinson ST, Sint K, Forester BP, Rhee TG. Effects of electroconvulsive therapy on functional outcomes among medicare patients with comorbid depression and dementia: A nationwide 1-year follow-up study. *J Clin Psychiatry.* (2023) 84. doi: 10.4088/JCP.22m14583

60. Green SL, Gignac GE, Watson PA, Brosnan N, Becerra R, Pestell C, et al. Apathy and depression as predictors of activities of daily living following stroke and traumatic brain injuries in adults: A meta-analysis. *Neuropsychol Rev.* (2022) 32:51–69. doi: 10.1007/s11065-021-09501-8